Tenderwize
Zurück zur Suche

Open-house discount agreement for Urapidil

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Dec 03, 2027 · 462 days left·Open·Supplies·Framework
Registrieren zum SpeichernOpen documents
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Urapidil, ATC C02CA06

52/100

Opportunity Score

Needs reviewMedium complexity
SuppliesFrameworkOpen
Warum diese Bewertung?

Chance

52 / 100

Komplexität

58 / 100

Risikofaktoren

Incorrect submission channel is explicitly disallowed; the buyer says documents must be submitted via the DTVP communic...

The monthly accession mechanism depends on receipt by the 3rd of the month, and paper originals must arrive by the 10th...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jan 2028
  • Non-exclusive open-house discount agreements for the medicinal product Urapidil, ATC C02CA06.
  • Supply of pharmaceutical products under identical, pre-set contract terms.
Vollständige Zusammenfassung anzeigen

This is an open-house supply arrangement for pharmaceutical discount agreements on Urapidil (ATC C02CA06) led by AOK Bayern. It is not a competitive award procedure in the usual sense: the buyer states that all interested pharmaceutical companies meeting the stated suitability requirement may join on identical, non-negotiable terms. The contract period runs from 2026-02-01 to 2028-01-31, with contract entry possible at any time until 2027-12-03. Submission is via DTVP electronic communication area with a qualified electronic signature, or by paper originals in duplicate; documents not in German must be submitted with a German translation. No contract value is provided.

Risiken

Incorrect submission channel is explicitly disallowed; the buyer says documents must be submitted via the DTVP communic...

The monthly accession mechanism depends on receipt by the 3rd of the month, and paper originals must arrive by the 10th...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • The contract and the annex 'Festlegung der vertragsgegenständlichen Arzneimittel' must be completed and signed.

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • A signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit) must be submitted.

Auftraggeber

Ort

München, DEU

Website

www.aok.de

Auftraggeberprofil

Profil öffnen

Kennung

DE811695320

Tätigkeit

Health

Lose (1)

LOT-0001

Open-house discount agreement for Urapidil

Open-house pharmaceutical discount agreement for the active substance Urapidil (ATC C02CA06). The lot is described as a supply arrangement for pharmaceutical products. The buyer states that the contract is non-exclusive, identical for all eligible companies, and not individually negotiable. Performance is in Germany, specifically the Bavaria region (DE212).

SuppliesFrameworkEU fundedElectronic submission

Ort

DE212, Germany

Dauer

Jan 2026 - Jan 2028

Kategorie

Pharmaceutical products

Frist

Deadline Dec 03, 2027

Vergabedetails

Veröffentlichungsdatum
14 Dec 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
831448-2025

Dokumente (2)

Vergabedokument 1Einreichungsportal 1

Ähnliche Ausschreibungen

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30